다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Cancer letters, v.415, 2018년, pp.86 - 105
Ribeiro, Andreia (Mountain Research Center (CIMO), ESA, Polytechnic Institute of Braganç) , Abreu, Rui M.V. (a) , Dias, Madalena M. (Mountain Research Center (CIMO), ESA, Polytechnic Institute of Braganç) , Barreiro, Maria Filomena (a) , Ferreira, Isabel C.F.R. (Laboratory of Separation and Reaction Engineering –)
AI-Helper
Abstract Angiogenesis is the natural and physiologic process of growing blood vessels from pre-existing ones. Pathological angiogenesis occurs when the precise balance of all the molecular pathways that regulate angiogenesis is disrupted, and this process is a critical step in many diseases, includ...
J. Org. Chem. Sun 11 249 2015 Natural phenolic metabolites with anti-angiogenic properties - a review from the chemical point of view
Nat. Med. Carmeliet 9 653 2003 10.1038/nm0603-653 Angiogenesis in health and disease
Chin. Chem. Lett. Gao 2015 10.1016/j.cclet.2015.07.016 Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors (II)
Nature Ferrara 438 967 2005 10.1038/nature04483 Angiogenesis as a therapeutic target
Adair 2010 Angiogenesis
Tomanek 441 2007 Anti-angiogenic Functional and Medicinal Foods Angiogenesis and cardiovascular diseases
Mandal 403 2007 Anti-angiogenic Functional and Medicinal Foods Angiogenesis in inflammatory arthritis
J. Med. Chem. Garofalo 55 1189 2012 10.1021/jm2013453 Synthesis and structure-activity relationships of (aryloxy) quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors
Bioorg. Med. Chem. Lett. Sanphanya 23 2962 2013 10.1016/j.bmcl.2013.03.042 Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach
Eur. J. Med. Chem. Gao 90 232 2015 10.1016/j.ejmech.2014.11.032 Discovery of novel VEGFR-2 inhibitors. Part II: biphenyl urea incorporated with salicylaldoxime
Semin. Cancer Biol. Baeriswyl 19 329 2009 10.1016/j.semcancer.2009.05.003 The angiogenic switch in carcinogenesis
Iran. J. Pharm. Res. Ebadi 13 405 2014 Analysis of a potent VEGFR-2 inhibitor: a case study on Motesanib
Nat. Med. Ferrara 9 669 2003 10.1038/nm0603-669 The biology of VEGF and its receptors
New Engl. J. Med. Escudier 356 125 2007 10.1056/NEJMoa060655 Sorafenib in advanced clear-cell renal-cell carcinoma
Lancet Motzer 370 2071 2007 10.1016/S0140-6736(07)61874-1 Targeted drugs for metastatic renal cell carcinoma
Eur. J. Med. Chem. Shi 84 698 2014 10.1016/j.ejmech.2014.07.071 Discovery of N-(2-phenyl-1H-benzo[d] imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors
Mini Rev. Med. Chem. Zhang 11 920 2011 10.2174/138955711797068355 Recent advances in antiangiogenic agents with VEGFR as target
Cancer Lett. Duvoix 223 181 2005 10.1016/j.canlet.2004.09.041 Chemopreventive and therapeutic effects of curcumin
Postepy Hig. Med. Dosw. Lewandowska 68 528 2014 10.5604/17322693.1102278 Synergistic interactions between anticancer chemotherapeutics and phenolic compounds and anticancer synergy between polyphenols
Losso 507 2007 Anti-angiogenic Functional and Medicinal Foods Screening functional foods as inhibitors of angiogenesis biomarkers
Bioorg. Med. Chem. Shen 23 1982 2015 10.1016/j.bmc.2015.03.022 Synthesis and structure-activity relationships of boswellic acid derivatives as potent VEGFR-2 inhibitors
Inter. J. Mol. Sci. Gavalas 14 15885 2013 10.3390/ijms140815885 Angiogenesis-related pathways in the pathogenesis of ovarian cancer
Carcinogenesis Labrecque 26 821 2005 10.1093/carcin/bgi024 Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound
J. Colloid Interface Sci. Rodríguez 461 285 2016 10.1016/j.jcis.2015.09.035 Effects of bleaching on osteoclast activity and their modulation by osteostatin and fibroblast growth factor 2
J. Burn Care Res. Ucuzian 31 158 2010 10.1097/BCR.0b013e3181c7ed82 Molecular mediators of angiogenesis
Cytokine Growth Factor Rev. Moss 24 579 2013 10.1016/j.cytogfr.2013.05.009 The angiopoietin:Tie 2 interaction: a potential target for future therapies in human vascular disease
J. Agric. Food Chem. Maeda-Yamamoto 47 2350 1999 10.1021/jf9811525 Effects of tea polyphenols on the invasion and matrix metalloproteinases activities of human fibrosarcoma HT1080 cells
Circ. Res. Visse 92 827 2003 10.1161/01.RES.0000070112.80711.3D Matrix metalloproteinases and tissue inhibitors of metalloproteinases
J. Mol. Med. Cao 86 785 2008 10.1007/s00109-008-0337-z Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
Life Sci. Behl 135 131 2015 10.1016/j.lfs.2015.06.017 Possible role of endostatin in the antiangiogenic therapy of diabetic retinopathy
World J. Clin. Oncol. Hagemann 3 67 2012 10.5306/wjco.v3.i5.67 A complete compilation of matrix metalloproteinase expression in human malignant gliomas
Biochim. Biophys. Acta Turner 1843 2563 2014 10.1016/j.bbamcr.2014.05.014 Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease
FASEB J. Mantovani 6 2591 1992 10.1096/fasebj.6.8.1592209 Cytokine regulation of endothelial cell function
Granger 23 2010 Inflammation and the Microcirculation Angiogenesis
Prog. Neurobiol. Gadient 52 379 1997 10.1016/S0301-0082(97)00021-X Interleukin-6 (il-6)-a molecule with both beneficial and destructive potentials
Eur. J. Cell Biol. Chalaris 90 484 2011 10.1016/j.ejcb.2010.10.007 The soluble Interleukin 6 receptor: generation and role in inflammation and cancer
Autoimmun. Rev. Fonseca 8 538 2009 10.1016/j.autrev.2009.01.012 Interleukin-6 as a key player in systemic inflammation and joint destruction
Biomed. Cent. Immunol. Li 9 1 2008 Functional imaging of interleukin 1 beta expression in inflammatory process using bioluminescence imaging in transgenic mice
Front. Physiol. Voronov 28 5 2014 The role IL-1 in tumor-mediated angiogenesis
Oncologist Horssen 11 397 2006 10.1634/theoncologist.11-4-397 TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility
Acta Pharmacol. Sin. Jin 31 1133 2010 10.1038/aps.2010.134 Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis
Rheumatology Horiuchi 49 1215 2010 10.1093/rheumatology/keq031 Transmembrane TNF-α: structure, function and interaction with anti-TNF agents
J. Nutr. Ruiz 136 664 2006 10.1093/jn/136.3.664 Functional diversity of flavonoids in the inhibition of the proinflammatory NF-κB, IRF, and Akt signaling pathways in murine intestinal epithelial cells
Biochim. Biophys. Acta Scheller 1813 878 2011 10.1016/j.bbamcr.2011.01.034 The pro- and anti-inflammatory properties of the cytokine interleukin-6
ASPET J. Ke 70 1469 2006 Hypoxia-inducible factor-1 (HIF-1)
Yale J. Biol. Med. Ziello 80 51 2007 Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia
Semin. Cancer Biol. Wang 35 S224 2015 10.1016/j.semcancer.2015.01.001 Broad targeting of angiogenesis for cancer prevention and therapy
Trends Immunol. Bonizzi 25 280 2004 10.1016/j.it.2004.03.008 The two NF-kB activation pathways and their role in innate and adaptive immunity
Eur. J. Cancer Gannon 49 2441 2013 10.1016/j.ejca.2013.02.026 Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer
Biochem. Biophys. Res. Commun. Niu 462 326 2015 10.1016/j.bbrc.2015.04.136 Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-kB p65 subunit nuclear import
PLoS One Adli 5 e9428 2010 10.1371/journal.pone.0009428 IKKα and IKKβ each function to regulate NF-κB activation in the TNF-induced/canonical pathway
Sci. STKE Häcker 357 re13 2006 Regulation and function of IKK and IKK-related kinases
J. Nutr. Pascual-Teresa 134 552 2004 10.1093/jn/134.3.552 Quercetin metabolites downregulate cyclooxygenase-2 transcription in human lymphocytes ex vivo but not in vivo
J. Neuroimmunol. Sil 291 115 2016 10.1016/j.jneuroim.2015.12.003 Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's disease
Ann. Rheum. Dis. Martel-Pelletier 62 501 2003 10.1136/ard.62.6.501 Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs
Bioorg. Med. Chem. Lokwani 23 4533 2015 10.1016/j.bmc.2015.06.008 Structure Based Library Design (SBLD) for new 1,4- dihydropyrimidine scaffold as simultaneous COX-1/COX-2 and 5-LOX inhibitors
J. Mol. Graph. Model. Aksakal 60 79 2015 10.1016/j.jmgm.2015.06.006 The study of dual COX-2/5-LOX inhibitors by using electronic-topological approach based on data on the ligand-receptor interactions
Oncotarget Ben-Batalla 6 6341 2015 10.18632/oncotarget.3437 Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Genes Cancer Casimiro 3 649 2012 10.1177/1947601913479022 Cyclins and cell cycle control in cancer and disease
Mol. Cancer Alao 6 24 2007 10.1186/1476-4598-6-24 The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention
Curr. Cancer Drug Targets Mazumder 4 65 2004 10.2174/1568009043481669 A dual role of cyclin e in cell proliferation and apotosis may provide a target for cancer therapy
Salajegheh 37 2016 Angiogenesis in Health, Disease and Malignancy Cyclin D1 and E1
Cancer Cell Kollmann 24 167 2013 10.1016/j.ccr.2013.07.012 A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis
Nat. Rev. Cancer Abbas 9 400 2009 10.1038/nrc2657 p21 in cancer: intricate networks and multiple activities
Eur. J. Pharmacol. Kim 615 150 2009 10.1016/j.ejphar.2009.05.015 Rosmarinic acid suppresses retinal neovascularization via cell cycle arrest with increase of p21WAF1 expression
Nat. Rev. Cancer Bieging 14 359 2014 10.1038/nrc3711 Unravelling mechanisms of p53-mediated tumour suppression
Biomed. J. Li 36 106 2013 10.4103/2319-4170.113230 Structure, function and regulation of the Hsp90 machinery
J. Funct. Foods He 18 10 2015 10.1016/j.jff.2015.06.052 Natural plant flavonoid apigenin directly disrupts Hsp90/Cdc37 complex and inhibits pancreatic cancer cell growth and migration
Top. Curr. Chem. Jackson 328 155 2013 10.1007/128_2012_356 Hsp90: structure and function
Curr. Cancer Drug Targets Staufer 10 890 2010 10.2174/156800910793357934 Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: a molecular target for anti-angiogenic therapy?
Vasc. Pharmacol. Abeyrathna 74 38 2015 10.1016/j.vph.2015.05.008 The critical role of Akt in cardiovascular function
Cell. Signal. Hers 23 1515 2011 10.1016/j.cellsig.2011.05.004 Akt signalling in health and disease
Curr. Opin. Genet. Dev. Pearl 15 55 2005 10.1016/j.gde.2004.12.011 Hsp90 and Cdc37 - a chaperone cancer conspiracy
Mol. Cell Vaughan 31 886 2008 10.1016/j.molcel.2008.07.021 Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37
Cell. Signal. Datta 27 2410 2015 10.1016/j.cellsig.2015.09.005 Hsp90/Cdc37 assembly modulates TGFβ receptor-II to act as a profibrotic regulator of TGFβ signaling during cardiac hypertrophy
J. Clin. Invest. Aikawa 100 1813 1997 10.1172/JCI119709 Oxidative stress activates extracellular signal-regulated kinases through Src and Ras cultured cardiac myocytes of neonatal rats
Immunobiology Manu 214 245 2009 10.1016/j.imbio.2008.10.002 Anti-metastatic potential of punarnavine, an alkaloid from Boerhaavia diffusa Linn
Development Shin 143 3796 2016 10.1242/dev.137919 Vegfa signals through ERK to promote angiogenesis, but not artery differentiation
Vasc. Pharmacol. Wang 49 158 2008 10.1016/j.vph.2008.07.005 Effect of β-escin sodium on endothelial cells proliferation, migration and apoptosis
Int. Rev. Cell Mol. Biol. Szabadfi 311 1 2014 10.1016/B978-0-12-800179-0.00001-5 Chapter one - neuropeptides, trophic factors, and other substances providing morphofunctional and metabolic protection in experimental models of diabetic retinopathy
NeoPlasia Zhang 15 591 2013 10.1593/neo.13158 Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models
Klement 487 2013 Platelets Chapter 24 - the role of platelets in angiogenesis
Blumenkranz 1213 2013 Retina Chapter 67 - pharmacotherapy of age-related macular degeneration
Vavvas 562 2013 Retina Chapter 26 - basic mechanisms of pathological retinal and choroidal angiogenesis
Clin. Ophthalmic Oncol. Seregard 11 2009 Chapter 3 - cancer pathology and angiogenesis
Am. J. Pathol. Albini 156 1381 2000 10.1016/S0002-9440(10)65007-9 Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells
J. Autoimmun. Indraccolo 43 244 2010 Interferon-α as angiogenesis inhibitor: learning from tumor models
J. Natl. Cancer Inst. Marschall 19 437 2003 10.1093/jnci/95.6.437 Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis
Exp. Eye Res. Filla 158 124 2017 10.1016/j.exer.2016.05.011 The role of integrins in glaucoma
Exp. Neurol. Lia 237 46 2012 10.1016/j.expneurol.2012.06.005 An angiogenic role for the α5β1 integrin in promoting endothelial cell proliferation during cerebral hypoxia
Theranostics Millard 1 154 2011 10.7150/thno/v01p0154 Integrin targeted therapeutics
J. Am. Acad. Dermatol Sauder 47 535 2002 10.1067/mjd.2002.124702 Neovastat (AE-941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis
Vasc. Pharmacol. Lee 47 313 2007 10.1016/j.vph.2007.08.009 (Æ-941) inhibits the airway inflammation via VEGF and HIF-2α suppression
Pharmacol. Ther. Harkness 148 17 2015 10.1016/j.pharmthera.2014.11.010 Asthma is not only an airway disease, but also a vascular disease
J. Ethnopharmacol. Ahn 110 476 2007 10.1016/j.jep.2006.10.006 Anti-inflammatory and anti-angiogenic activities of Gastrodia elata Blume
J. Theor. Biol. Dormanns 394 1 2016 10.1016/j.jtbi.2016.01.009 The role of nitric oxide in neurovascular coupling
Nitric Oxide El-Sehemy 54 30 2016 10.1016/j.niox.2016.02.002 Nitric oxide signaling in human ovarian cancer: a potential therapeutic target
Cardiovasc. Res. Bir 95 7 2012 10.1093/cvr/cvs143 Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischemic tissue diseases
Biochimie Lee 121 131 2016 10.1016/j.biochi.2015.12.005 Regulation of protein kinase CK2 catalytic activity by protein kinase C and phospholipase D2
Bioorg. Med. Chem. Łukowska-Chojnacka 24 735 2016 10.1016/j.bmc.2015.12.041 Synthesis of novel polybrominated benzimidazole derivatives - potential CK2 inhibitors with anticancer and proapoptotic activity
Adv. Clin. Exp. Med. Montenarh 23 153 2014 10.17219/acem/37040 Protein kinase CK2 and angiogenesis
Mol. Cancer Zhao 10 104 2011 10.1186/1476-4598-10-104 Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90
Cardiovasc. Diabetol. Moriya 14 19 2015 10.1186/s12933-015-0180-9 Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells
Biochem. Pharmacol. Quintieri 89 162 2014 10.1016/j.bcp.2014.02.018 Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications
Eur. J. Med. Chem. Barbosa 71 1 2014 10.1016/j.ejmech.2013.10.058 Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
J. Vasc. Interv. Radiol. Oklu 21 1791 2010 10.1016/j.jvir.2010.08.009 Angiogenesis and current antiangiogenic strategies for the treatment of cancer
FDA, Consulted in 03/05/2016: https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm193900.htm.
Clin. Ther. Shih 28 1779 2006 10.1016/j.clinthera.2006.11.015 Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies
Cell Potente 146 873 2011 10.1016/j.cell.2011.08.039 Basic and therapeutic aspects of angiogenesis
National Cancer Institute consulted in 03/05/2016: http://www.cancer.gov/about-cancer/treatment/drugs/fda-vandetanib.
Nat. Rev. Dis. Prim. Hsieh 3 17009 2017 10.1038/nrdp.2017.9 Renal cell carcinoma
Angiogenesis Gotink 13 1 2010 10.1007/s10456-009-9160-6 Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
ChemMedChem Iacopetta 12 381 2017 10.1002/cmdc.201600629 Old drug scaffold, new activity: thalidomide-correlated compounds exert different effects on breast cancer cell growth and progression
Mol. Med. Rep. Qu 14 4781 2016 10.3892/mmr.2016.5797 Lenalidomide induces apoptosis and inhibits angiogenesis via caspase-3 and VEGF in hepatocellular carcinoma cells
Angiogenesis Lu 2016 10.1007/s10456-016-9512-y Plants and their active compounds: natural molecules to target angiogenesis
Clin. Colorectal Cancer Lee 13 135 2014 10.1016/j.clcc.2014.02.001 Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer
Eur. Urol. Bhojani 53 917 2008 10.1016/j.eururo.2007.11.037 Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Pharmacol. Res. Nobili 59 365 2009 10.1016/j.phrs.2009.01.017 Natural compounds for cancer treatment and prevention
Curr. Oncol. Sagar 13 14 2006 10.3747/co.v13i1.77 Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer - Part 1
J. Evid. Based Complement. Altern. Med. Seo 2013 1 2013 Antiangiogenic activity and pharmacogenomics of medicinal plants from traditional Korean medicine
Pharmacol. Rep. Zhu 65 410 2013 10.1016/S1734-1140(13)71016-8 Effects of sesquiterpene, flavonoid and coumarin types of compounds from Artemisia annua L. on production of mediators of angiogenesis
Eur. J. Med. Chem. Ghalib 47 601 2012 10.1016/j.ejmech.2011.10.037 A novel caryophyllene type sesquiterpene lactone from Asparagus falcatus (Linn.); structure elucidation and anti-angiogenic activity on HUVECs
Food Funct. Guimarães 7 79 2016 10.1039/C5FO00586H Wild Roman chamomile extracts and phenolic compounds: enzymatic assays and molecular modelling studies with VEGFR-2 tyrosine kinase
J. Ethnopharmacol. Huang 175 185 2015 10.1016/j.jep.2015.09.021 Potent anti-angiogenic component in Croton crassifolius and its mechanism of action
Microvasc. Res. Al-Salahi 90 30 2013 10.1016/j.mvr.2013.07.007 Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function
Food Chem. Toxicol. Bostancıoǧlu 50 2002 2012 10.1016/j.fct.2012.03.074 Assessment of anti-angiogenic and anti-tumoral potentials of Origanum onites L. essential oil
Ind. Crops Prod. Kadria 54 6 2014 10.1016/j.indcrop.2013.12.051 Antiangiogenic activity of neutral lipids, glycolipids, and phospholipids fractions of Pinus halepensis Mill. seeds
Phytochem. Lett. Nguyen 12 69 2015 10.1016/j.phytol.2015.02.012 Cytotoxic and anti-angiogenic effects of lanostane triterpenoids from Ganoderma lucidum
J. Ethnopharmacol. Lee 131 56 2010 10.1016/j.jep.2010.05.064 Anti-angiogenic activity of methanol extract of Phellinus linteus and its fractions
J. Funct. Foods Lin 17 802 2015 10.1016/j.jff.2015.06.015 Antioxidant and anti-angiogenic effects of mushroom phenolics-rich fractions
Nutr. Cancer Mertens-Talcott 133 2669 2003 Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in molt-4 human leukemia cells
Cancer Lett. Mertens-Talcott 218 141 2005 10.1016/j.canlet.2004.06.007 Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells
Biochemistry Bagchi 69 75 2004 Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula
J. Nutr. Zhou 133 516 2003 10.1093/jn/133.2.516 Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice
Inter. J. Cancer Zhou 108 8 2004 10.1002/ijc.11549 Combined inhibition of estrogen-dependent humen breast carcinoma by soy and tea bioactive components in mice
Cancer Prev. Res. Paur 3 653 2010 10.1158/1940-6207.CAPR-09-0089 Extract of oregano, coffee, thyme, clove, and walnuts inhibits nf-κb in monocytes and in transgenic reporter mice
Vasc. Pharmacol. Kim 51 262 2009 10.1016/j.vph.2009.06.010 Anti-angiogenic effect of caffeic acid on retinal neovascularization
Biochem. Biophys. Res. Commun. Liu 413 299 2011 10.1016/j.bbrc.2011.08.091 Acacetin inhibits VEGF expression, tumor angiogenesis and growth through AKT/HIF-1α pathway
Redox Biol. Banerjee 5 153 2015 10.1016/j.redox.2015.04.009 Oxidative stress triggered by naturally occurring flavone apigenin results in senescence and chemotherapeutic effect in human colorectal cancer cells
Toxicol. Lett. Wu 224 157 2014 10.1016/j.toxlet.2013.10.007 Apigenin potentiates the growth inhibitory effects by IKK-β-mediated NF-κB activation in pancreatic cancer cells
Inter. J. Cancer Rodriguez 118 1635 2006 10.1002/ijc.21545 Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex
J. Ocul. Pharmacol. Ther. Wang 21 107 2005 10.1089/jop.2005.21.107 Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1α in a mouse model of oxygen-induced retinopathy
Biomed. Prev. Nutr. Rathinasamy 4 469 2014 10.1016/j.bionut.2014.07.002 Effect of genistein on regenerative angiogenesis using zebrafish as model organism
Life Sci. Pu 93 791 2013 10.1016/j.lfs.2013.09.025 The antiangiogenic activity of Kushecarpin D, a novel flavonoid isolated from Sophora flavescens Ait
Food Chem. Toxicol. Johnson 60 83 2013 10.1016/j.fct.2013.07.036 Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro
Eur. J. Pharmacol. Zhao 723 360 2014 10.1016/j.ejphar.2013.10.069 Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells
Food Chem. Fortes 134 134 2012 10.1016/j.foodchem.2012.02.079 Evaluation of the anti-angiogenic potential of hydroxytyrosol and tyrosol, two bio-active phenolic compounds of extra virgin olive oil, in endothelial cell cultures
FASEB J. Bråkenhielm 15 1798 2001 10.1096/fj.01-0028fje Suppression of angiogenesis, tumor growth,and wound healing by resveratrol, a natural compound in red wine and grapes
Cancer Lett. Igura 171 11 2001 10.1016/S0304-3835(01)00443-8 Resveratrol and quercetin inhibit angiogenesis in vitro
Cytokine Zhang 76 549 2015 10.1016/j.cyto.2015.06.019 SIRT1 mediated inhibition of VEGF/VEGFR2 signaling by resveratrol and its relevance to choroidal neovascularization
Eur. J. Pharm. Sci. Cullberg 49 251 2013 10.1016/j.ejps.2013.02.014 Resveratrol has inhibitory effects on the hypoxia-induced inflammation and angiogenesis in human adipose tissue in vitro
BMC Compl. Altern. Med. Lopes 9 1 2009 10.1186/1472-6882-9-15 Anti-angiogenic effects of pterogunidine alkaloid isolated from Alchornea glandulosa
Chem. Biol. Interact. Saraswati 206 204 2013 10.1016/j.cbi.2013.09.007 Punarnavine, an alkaloid from Boerhaavia diffusa exhibits anti-angiogenic activity via downregulation of VEGF in vitro and in vivo
Integr. Cancer Ther. Zhao 13 520 2014 10.1177/1534735414547109 Total alkaloids of Rubus alceifolius poir shows anti-angiogenic activity in vivo and in vitro
Mol. Cell. Biochem. Ganesan 380 1 2013 10.1007/s11010-013-1651-5 Marine algal carotenoids inhibit angiogenesis by down-regulating FGF-2-mediated intracellular signals in vascular endothelial cells
J. Funct. Foods Kuhnen 1 284 2009 10.1016/j.jff.2009.04.001 Antiangiogenic properties of carotenoids: a potential role of maize as functional food
Cancer Lett. Huang 264 101 2008 10.1016/j.canlet.2008.01.043 Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression
Blood Sethi 109 2727 2007 10.1182/blood-2006-10-050807 Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kB-regulated gene products and TAK1-mediated NF-kB activation
Biol. Pharm. Bull. Matsuda 20 1092 1997 10.1248/bpb.20.1092 Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals
J. Ethnopharmacol. Zhong 141 721 2012 10.1016/j.jep.2011.08.052 Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo
J. Ethnopharmacol. Chan 137 64 2011 10.1016/j.jep.2011.04.021 Polyphyllin D, a steroidal saponin from Paris polyphylla, inhibits endothelial cell functions in vitro and angiogenesis in zebrafish embryos in vivo
Curr. Trends Biotechnol. Pharm. Prasanna 3 138 2009 Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor
Oncol. Rep. Lee 30 933 2013 10.3892/or.2013.2487 Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway
Silico Pharmacol. Saha 1 11 2013 10.1186/2193-9616-1-11 Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera's key metabolite Withaferin A
Angiogenesis Mohan 7 115 2004 10.1007/s10456-004-1026-3 Withaferin A is a potent inhibitor of angiogenesis
Mol. Cancer Ther. Gao 13 2930 2014 10.1158/1535-7163.MCT-14-0324 Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K
Bioinformation Chatterjee 8 1249 2012 10.6026/97320630081249 Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
Pharmacol. Ther. Reddy 99 1 2003 10.1016/S0163-7258(03)00042-1 Natural products for cancer prevention: a global perspective
Nat. Nanotechnol. Peer 2 751 2007 10.1038/nnano.2007.387 Nanocarriers as an emerging platform for cancer therapy
AAPS J. Wang 15 834 2014 Enhancing the antitumor activity of berberine hydrochloride by solid lipid nanoparticle encapsulation
Cancer Res. Siddiqui 69 1712 2009 10.1158/0008-5472.CAN-08-3978 Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate
Nanoscale Gou 3 1558 2011 10.1039/c0nr00758g Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo
Int. J. Clin. Exp. Med. Huang 8 8369 2015 Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution
Curr. Oncol. Rep. Tannir 19 14 2017 10.1007/s11912-017-0566-9 Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma
Clin. Oncol. Sleijfer 27 3126 2009 10.1200/JCO.2008.21.3223 Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group
Curr. Opin. Investig. Drugs Krupitskaya 10 597 2009 Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer
Mol. Cancer Ther. Abou-Elkacem 12 1322 2013 10.1158/1535-7163.MCT-12-1162 Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model
Proc. Natl. Acad. Sci. D'Amato 91 4082 1994 10.1073/pnas.91.9.4082 Thalidomide is an inhibitor of angiogenesis
Clin. Oncol. Valerio 6555 30110 2017 Targeted therapy in thyroid cancer: state of the art
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.